- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01673087
Stress Biomarkers:Attaching Biological Meaning to Field Friendly Salivary Measures
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan Health System
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Medically healthy volunteers, ages 18 to 50 years
Exclusion Criteria:
- Pregnancy
- Irregular menses, medications or drugs that effect HPA axis
- Most psychiatric disorders
- Medical problems that effect HPA axis or increase risks involved in participation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: laboratory HPA probes
All subjects will be studied with multiple probes of HPA axis function over the course of one to two months: Metyrapone, oral, 750 mg, administered twice 3.5 hrs apart; Dexamethasone, oral, 1.5 mg administered once; oral, 0.25 mg administered once; Corticorelin ovine triflutate (CRH), intravenous, 100 mcg, administered once over 30 seconds; Cortrosyn (ACTH), intravenous, 250 mcg, administered once by bolus. |
750 mcg, oral, administered twice, 3.5 hours apart
Other Names:
Administered twice: 1.5 mg, oral, at 11 pm And 0.25 mg, oral, at bedtime at least one week before or after other administration.
Other Names:
250 mcg, IV, bolus, in the afternoon.
Other Names:
100 mcg, IV, over 30 seconds, in the afternoon.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
cortisol levels
Time Frame: Primarily measuring change from pre-drug baseline to peak occuring about 20 minutes to an hour later
|
cortisol measured in saliva and in blood.
|
Primarily measuring change from pre-drug baseline to peak occuring about 20 minutes to an hour later
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
corticotropin (ACTH)
Time Frame: Primarily measuring change from pre-drug baseline to peak occuring about 10 minutes to an hour later
|
ACTH will be measured in blood using chemoluminescence detection.
|
Primarily measuring change from pre-drug baseline to peak occuring about 10 minutes to an hour later
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: James L Abelson, MD, University of Michigan
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Anti-Inflammatory Agents
- Antimetabolites
- Antineoplastic Agents
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Dexamethasone
- Cosyntropin
- Metyrapone
- Adrenocorticotropic Hormone
- Corticotropin-Releasing Hormone
Other Study ID Numbers
- 1R01MH093486-01A1 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stress
-
Massachusetts General HospitalCompletedStress | Emotional Stress | Psychological Stress | Social Stress | Life StressUnited States
-
University of California, Los AngelesUniversity of California, San Francisco; Stanford University; California Initiative...Enrolling by invitationStress | Stress, Psychological | Stress, Emotional | Stress, Physiological | Stress ReactionUnited States
-
University of PadovaRecruitingStress | Stress Disorder | Work Related StressItaly
-
Duquesne UniversityUniversity of California, San Diego; West Penn Allegheny Health System; El Centro... and other collaboratorsTerminated
-
University of Sao PauloCompleted
-
Syracuse VA Medical CenterUS Department of Veterans AffairsCompletedEmotional Stress | Psychological Stress | Life StressUnited States
-
Dana-Farber Cancer InstituteEnrolling by invitationStress | Post Traumatic Stress Disorder | Work Related StressUnited States
-
Royal Cornwall Hospitals TrustEnrolling by invitationStress | Stress, Psychological | Stress, JobUnited Kingdom
-
Taichung Veterans General HospitalUnknown
-
Northumbria UniversityVolac International LtdRecruitingStress | Mood | Physiological StressUnited Kingdom
Clinical Trials on Metyrapone
-
HRA PharmaCompletedCushing's SyndromeGermany, Belgium, Italy, Hungary, Poland, Romania, Spain, Turkey
-
Istituto Auxologico ItalianoHRA PharmaRecruiting
-
Jane BarnesNational Institute for Health Research, United KingdomCompleted
-
Baker Heart Research InstituteUnknownObesity | Metabolic Syndrome | Insulin ResistanceAustralia
-
National Center for Research Resources (NCRR)University of TexasUnknownBrain Injury | Craniocerebral TraumaUnited States
-
Nationwide Children's HospitalCompletedAdrenal Insufficiency | Prader Willi SyndromeUnited States
-
Universitätsklinikum Hamburg-EppendorfCompleted
-
Mayo ClinicRecruitingAutonomous Cortisol Secretion | Mild Autonomous Cortisol Secretion (MACS)United States
-
GlaxoSmithKlineCompletedDepressive Disorder and Anxiety DisordersUnited Kingdom
-
Eleonora SeeligCompletedGlucocorticoid EffectSwitzerland